Who Owns Kenvue and Its History

Kenvue is a well-established company with a rich history. Founded in 1945, it has been a leading player in the consumer goods industry for over 75 years.

Kenvue was originally known as Colgate-Palmolive. It wasn't until 2021 that the company rebranded itself as Kenvue.

Colgate-Palmolive, the precursor to Kenvue, was founded by William Colgate and Samuel Colgate in 1806. The company started out as a soap and candle business.

Explore further: Kenvue Stock Quote

Kenvue became a fully independent company on August 23, 2023, following its separation from Johnson & Johnson. This marked a historic moment for the company.

The separation was made possible through an exchange offer, where Johnson & Johnson accepted 190,955,436 shares of its common stock in exchange for 1,533,830,450 shares of Kenvue common stock. As a result, Johnson & Johnson now owns 9.5% of the outstanding shares of Kenvue common stock.

Kenvue is now a standalone entity, free to focus on delivering innovative care solutions to customers and consumers around the world. The company's CEO, Thibaut Mongon, expressed his excitement for this new chapter in the company's history.

Here's a breakdown of Kenvue's ownership structure:

Kenvue's institutional investors, such as Vanguard Group and BlackRock, hold significant sway over the company's governance and strategic decisions.

Kenvue Inc is a consumer health company that was formed as a spinoff from Johnson & Johnson in 2023. It focuses on managing brands that include Neutrogena, Tylenol, and Band-Aid. The company's initial public offering (IPO) was priced at $22 per share, raising approximately $3.8 billion.

Kenvue's stock has seen positive momentum, with shares trading around $25.30 as of September 2023, marking a year-to-date increase of over 15%. The company's market capitalization has reached approximately $41 billion. Kenvue's revenue for Q2 2023 was $1.5 billion, with a net income of $215 million and an earnings per share (EPS) of $0.27.

Here's a breakdown of Kenvue's ownership structure:

Kenvue Inc was formed as a spinoff from Johnson & Johnson in 2023, marking a significant milestone in the company's history.

Kenvue commenced operations as a standalone entity in 2023, focusing on consumer health products.

The company filed with the U.S. Securities and Exchange Commission (SEC) in May 2023 in preparation for its initial public offering (IPO).

Suggestion: Kenvue Stock Swap

Kenvue priced its IPO at $22 per share, raising approximately $3.8 billion on May 18, 2023.

By the end of its first trading day on May 19, 2023, Kenvue's stock rose to $24.21, reflecting an increase of 10% from its IPO price.

Here are the key financial metrics from Kenvue's IPO:

As of September 2023, Kenvue's stock continued to see positive momentum, with shares trading around $25.30.

Kenvue Inc is a consumer health company that was spun off from Johnson & Johnson in 2023. It became a publicly traded company on May 4, 2023, under the ticker symbol "KVUE".

Kenvue's largest shareholders are institutional investors, who hold approximately 70% of the company's shares. The largest institutional investors include Vanguard Group and BlackRock.

The company's ownership structure is a mix of institutional and individual investors, with notable individual investors being company insiders, who own around 5% of the shares. Kenvue raised approximately $3.8 billion through its initial public offering (IPO), with an initial stock price of $22 per share.

A different take: Kenvue Dividend

Kenvue's market capitalization has reached approximately $40 billion, demonstrating robust investor confidence in its long-term business model and growth potential. The company aims to leverage its established brands in the consumer health space, including products like Tyleno, Listerine, and Neutrogena.

Here's a breakdown of Kenvue's ownership categories:

Johnson & Johnson still holds a significant stake in Kenvue, owning approximately 9.5% of the company's shares after exchanging 1.5 billion shares for 190 million shares of Johnson & Johnson common stock.

Johnson & Johnson owns 90.9% of Kenvue, and shareholders will receive shares of Kenvue for each share of JNJ they own by the end of 2023.

The exact number of shares of Kenvue that will be given per share owned of JNJ is currently unclear, but it will be announced in the coming months.

Shareholders of Johnson & Johnson will be free to buy, sell, or hold their shares of Kenvue once they are distributed from JNJ.